spacer
home > pmps > winter 2003 > primary production of biopharmaceuticals in plants - an economically attractive choice?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Primary Production of Biopharmaceuticals in Plants - An Economically Attractive Choice?

Plants as Alternative Eukaryotic Expression Systems

The progress of molecular plant genetics, and particularly of transgene expression in plants, has spurred the interest of academia and companies to consider them as eukaryotic hosts for biopharmaceutical production and as an additional or even alternative system to established mammalian cell culture (CHO) and yeast fermentation (1). Two arguments favouring plant hosts have frequently been quoted, namely safety - the absence of adventitious mammalian viral or prionic contamination - and the unlimited scalability of production.

Whether the future launch of biogenerics and the market introduction of numerous new therapeutic monoclonal antibodies will really be accompanied by a strong capacity shortage in primary production, as often predicted, is as yet uncertain. Therefore it is worthwhile to analyse whether plant expression systems have the potential to become an additional sourcing route for biopharmaceutical active ingredients in collaboration with, and as a feasible technological extension of, established mammalian cell culture and microbial fermentation.

From the viewpoint of the pharmaceutical industry, the prerequisites that a new expression system must fulfil are as follows:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Detlef Wilke, Partner at Biotech Consulting GmbH and Jens A Katzek, Managing Director of BIO-Mitteldeutschland GmbH

Dr Detlef Wilke is a Microbiologist, and since 1992 has operated a consulting company specialising in biotechnology. Together with his partners at the firm, he published technology and cost structure analysis of recombinant and conventional biotech products. Prior to his consulting business he worked for 15 years in R&D and business development with Schering AG and Solvay & Cie. In June 2003 he became a Member of the management board of Icon Genetics AG, Munich.

Dr Jens A Katzek is a Biochemist, and since January 2003 has been Managing Director of BIO-Mitteldeutschland GmbH. Prior to this position he was Managing Director of the German Association of Biotechnology Industries (DIB), has worked as the Head of Corporate Communications with the seed company KWS SAAT AG, and was responsible for the international environmental policy of BUND - Friends of the Earth, Germany.


spacer
Dr Detlef Wilke
spacer
spacer
spacer
Dr Jens A Katzek
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Applikon Biotechnology launches fully customizable single-use bioreactor using 3D printing technology

Dutch-based upstream bioprocess equipment specialist Applikon Biotechnology B.V. (Applikon) has launched the single-use AppliFlex ST lab-scale bioreactor as a significant extension to its range of innovative bioreactor systems. AppliFlex ST is a fully customizable and scalable stirred tank single-use bioreactor that uses 3D printing technology to provide a head plate that is uniquely configured to each individual process, including custom impeller design, and different sample port connections.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement